Clinical Trial Update: Olutasidenib in Relapsed IDH1 Mutated AML Patients Who Have Previously Received Venetoclax [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating olutasidenib in relapsed IDH1-mutated acute myeloid leukemia patients who have previously received venetoclax; the study status …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Olutasidenib (olutasidenib)

Snippet

Sponsor: Timothy Pardee | Conditions: IDH1 Mutation, Relapsed / Refractory AML | Phase 2 | Status: NOT_YET_RECRUITING